Evidence map›Paper›PMID 42514900›Full record

ArticlePharmaceutics2026

Promising Glaucoma Medication: A Comprehensive Translational Evaluation.

Doaa Nabih Maria, Mohamed Moustafa Ibrahim, Sara N Maria, Monica M Jablonski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Doaa Nabih MariaDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Mohamed Moustafa IbrahimDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0001-7691-6128
Sara N MariaDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0009-0005-5845-8270
Monica M JablonskiDepartment of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-4021-3559

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
Novel Extended Release Glaucoma Therapy for Once Daily DosingR24EY029950 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JABLONSKI, MONICA M · 2020 to 2024
$5.3M
Mass Spectrometer for Small Molecule Drug DevelopmentS10OD016226 · OD · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MEIBOHM, BERND · 2014 to 2014
$316k
NEI NIH HHS R24 EY029950NIH HHS P51 OD011133NIH HHS S10 OD016226
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

enhanced delivery formulationex vivo transcorneal permeabilityglaucomain vivo bioadhesionnon-human primates

Identifiers

PMID42514900
PMCPMC13414610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.